Authorizing Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy11514

POLICY TYPE
Policy document

LAST REVIEWED
2020-02-29

DATE
2015-02-28

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Bill C-45: The Cannabis Act
https://policybase.cma.ca/link/policy13861

**POLICY TYPE**  Parliamentary submission
**DATE**  2018-04-18
**TOPICS**  Pharmaceuticals, prescribing, cannabis, drugs

**Documents**

Canada's lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

**POLICY TYPE**  Policy endorsement
**DATE**  2017-05-26
**TOPICS**  Pharmaceuticals, prescribing, cannabis, drugs

**Documents**
Cannabis for Medical Purposes
https://policybase.cma.ca/link/policy10045

POLICY TYPE: Policy document
LAST REVIEWED: 2019-03-03
DATE: 2010-12-04
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

CANNABIS FOR MEDICAL PURPOSES

Date: December 4, 2010

The Canadian Medical Association (CMA) has always recognized the virtue of requirements of harm reduction, voluntary participation and control for which commercial production and use have been effective in many countries and provinces.

Prisoners have a right to medical care. Medical care should be provided for prisoners as required, and the need should be reviewed periodically.

We believe that for medical use to be effective, access to medical cannabis should be ensured.

Medical cannabis has been shown to be effective in the treatment of cancer, epilepsy, and multiple sclerosis.

We believe that the Government of Canada should support the development and implementation of a national strategy for cannabis use in medicine, including the regulation of cannabis for medical purposes.

We believe that the Government of Canada should support the development and implementation of a national strategy for cannabis use in medicine, including the regulation of cannabis for medical purposes.

The CMA endorses the following recommendations:

1. The CMA recommends that the federal government support the development and implementation of a national strategy for cannabis use in medicine, including the regulation of cannabis for medical purposes.

2. The CMA recommends that the federal government support the development and implementation of a national strategy for cannabis use in medicine, including the regulation of cannabis for medical purposes.

3. The CMA recommends that the federal government support the development and implementation of a national strategy for cannabis use in medicine, including the regulation of cannabis for medical purposes.

The CMA endorses the following recommendations:

1. The CMA recommends that the federal government support the development and implementation of a national strategy for cannabis use in medicine, including the regulation of cannabis for medical purposes.

2. The CMA recommends that the federal government support the development and implementation of a national strategy for cannabis use in medicine, including the regulation of cannabis for medical purposes.

3. The CMA recommends that the federal government support the development and implementation of a national strategy for cannabis use in medicine, including the regulation of cannabis for medical purposes.
CMA’s Recommendations for Bill S-5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13641

POLICY TYPE
Parliamentary submission

DATE
2017-04-07

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S-5 An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts

https://policybase.cma.ca/link/policy13918

POLICY TYPE  Parliamentary submission
DATE  2018-02-15
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Health care and patient safety

Documents
Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE  Response to consultation
DATE  2017-12-07
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission: Excise Duty Framework for Cannabis Products

Submission to the Government of Canada consultation on the proposed excise duty framework for cannabis products

December 7, 2017
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE
Response to consultation

DATE
2018-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on potential market for cannabis health products that would not require practitioner oversight

https://policybase.cma.ca/link/policy14125

**POLICY TYPE**
Response to consultation

**DATE**
2019-09-03

**TOPICS**
Health care and patient safety
Population health, health equity, public health

**Documents**
The Health risks and harms associated with the use of marijuana
https://policybase.cma.ca/link/policy11138

POLICY TYPE  Parliamentary submission
DATE  2014-05-27
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Legalization, regulation and restriction of access to marijuana
https://policybase.cma.ca/link/policy11954

POLICY TYPE Response to consultation
DATE 2016-08-29
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission
Legalization, Regulation and Restriction of Access to Marijuana

Government of Canada – Task Force on Marijuana
Legalization and Regulation

August 29, 2016

STATEMENT | DÉCLARATION

Chief Statement – Legalization of Marijuana

July 31, 2016 – The CMA’s response to the Task Force on Marijuana’s draft report on the proposed approach to the regulation of cannabis.

It is clear to the CMA that the current system is not working. A system that fails to protect the health and safety of all Canadians must be replaced.

The CMA recommends that regulations be evidence-based, and recognize the contribution of the health-care system.

The CMA recommends that the government’s proposed structure for the regulation and sale of cannabis is clear and consistent.

The CMA recommends that any proposal to legalize the possession of cannabis be evidence-based.

The CMA recommends that the proposed structure for the distribution of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the regulation of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the sale of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the use of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the education of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the enforcement of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the regulation of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the sale of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the use of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the education of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the enforcement of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the regulation of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the sale of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the use of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the education of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the enforcement of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the regulation of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the sale of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the use of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the education of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the enforcement of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the regulation of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the sale of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the use of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the education of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the enforcement of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the regulation of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the sale of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the use of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the education of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the enforcement of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the regulation of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the sale of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the use of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the education of cannabis be evidence-based.

The CMA recommends that the government’s proposed structure for the enforcement of cannabis be evidence-based.
Proposed approach to the regulation of cannabis
https://policybase.cma.ca/link/policy13838

POLICY TYPE
Response to consultation

DATE
2018-01-19

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs